XyloCor Therapeutics is dedicated to advancing gene therapy as a treatment for advanced coronary artery disease, particularly focusing on patients with refractory angina who have limited treatment options. Their lead investigational product, XC001, aims to stimulate the formation of new coronary blood vessels, thereby improving blood supply to the heart and alleviating debilitating chest pain associated with ischemia. This innovative approach is supported by both pre-clinical and clinical evidence, and the company has completed enrollment for its Refractory Angina trial, with an Investigational New Drug (IND) application currently open with the FDA.

In addition to XC001, XyloCor is developing XC002, which targets cardiac tissue regeneration in patients suffering from heart failure due to past heart attacks. This program has shown promise in transforming non-functioning cardiac cells into functional ones in animal models. The company’s commitment to addressing significant unmet clinical needs in cardiovascular disease is further exemplified by their collaboration with SmartCella for the use of the Extroducer Infusion Catheter System, which will facilitate the administration of their novel gene therapies. Overall, XyloCor Therapeutics is at the forefront of developing gene therapy solutions that could significantly enhance the quality of life for patients with severe cardiovascular conditions.

United States

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.

XyloCor Therapeutics

Company Details